Skip to main content
ArticleOPEN ACCESS

Re: Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer [3]

Journal of the National Cancer Institute
DOI: 10.1093/jnci/dji037
0Citations
Citations of this article
4Readers
Mendeley users who have this article in their library.

References Powered by Scopus

A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma

Journal of the National Cancer Institute
1520Citations
N/AReaders
Get full text

Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer

Journal of the National Cancer Institute
1059Citations
N/AReaders
Get full text

Randomised controlled study of effect of parathyroid hormone on vertebral-bone mass and fracture incidence among postmenopausal women on oestrogen with osteoporosis

Lancet
695Citations
N/AReaders
Get full text
View more at Scopus

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Grenader, T., Shavit, L., Uziely, B., & Peretz, T. (2005, February 2). Re: Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer [3]. Journal of the National Cancer Institute. https://doi.org/10.1093/jnci/dji037

Readers' Seniority

Tooltip

Professor / Associate Prof. 2

67%

Researcher 1

33%

Readers' Discipline

Tooltip

Medicine and Dentistry 4

100%

Save time finding and organizing research with Mendeley

Sign up for free